REGN - Company ID 0000872589
The table below shows REGENERON PHARMACEUTICALS, INC.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B |
| Short-term investments | $5.49B | $6.52B | $8.11B | $4.64B | $2.81B | $1.39B |
| Receivables | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $3.11B |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $18.02B |
| $18.66B |
| $19.48B |
| $15.88B |
| $14.01B |
| $9.78B |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B |
| Accounts payable | $939.00M | $789.50M | $606.60M | $589.20M | $564.00M | $475.50M |
| Total current liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B |
| Long-term debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B |
| Total liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B |
| Retained earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B |
| Total equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B |